Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876525 | 0.91 | ADH5 (0.63) | ADH5TACR3 | |
| SCHEMBL1516242 | 0.91 | ADH5 (0.63) | ADH5TACR3 | |
| SCHEMBL876974 | 0.91 | ADH5 (0.63) | ADH5TACR3 | |
| SCHEMBL15965802 | 0.86 | ADH5 (0.66) | ADH5TACR3 | |
| SCHEMBL873520 | 0.81 | ADH5 (0.77) | ADH5TACR3 | |
| SCHEMBL872907 | 0.81 | ADH5 (0.77) | ADH5TACR3 | |
| SCHEMBL1515742 | 0.81 | ADH5 (0.77) | ADH5TACR3 | |
| SCHEMBL877153 | 0.79 | ADH5 (0.78) | ADH5TACR3 | |
| SCHEMBL1516314 | 0.77 | ADH5 (0.59) | ADH5TACR3 | |
| SCHEMBL877384 | 0.77 | ADH5 (0.59) | ADH5TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | disclosed |
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | ADH5 103/4885TACR3 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.